Literature DB >> 20381482

Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease?

Morten Asser Karsdal1, Kim Henriksen, Diana Julie Leeming, Thasia Woodworth, Efstathios Vassiliadis, Anne-Christine Bay-Jensen.   

Abstract

The aim of this review is to discuss the potential usefulness of novel advances in the class of biochemical markers, neo-epitopes. Neo-epitopes are post-translational modifications (PTMs) of proteins formed by processes such as protease cleavage, citrullination, nitrosylation, glycosylation and isomerization. Each modification results from a specific local physiological or pathobiologial process. Identification of each modification, and the affected tissue-specific protein, may produce a unique disease-specific biochemical marker. One example of neo-epitopes detectable in protein fragments are type II collagen degradation products. These 2nd generation biochemical markers have proven useful for research on joint damage. Such neo-epitopes are being utilized in translational medicine to estimate safety and efficacy in both preclinical models and clinical settings. More advanced, 3rd generation biochemical markers, which may more accurately identify both the affected tissue and the disease stage, might be developed through research into multiple PTMs occurring during specific disease pathogenesis. The end-product of these investigations is one single measurement for each disease. To date, advanced biochemical markers have been identified in bone, cardiovascular, fibrosis and cartilage diseases and continue research in Alzheimer's and chronic obstructive pulmonary diseases. These advanced biochemical marker assays relying on analytes that are modified by multiple PTMs may become optimal tools that meet the BIPED (Burden of disease, Investigatory, Prognostic, Efficacy of intervention and Diagnosis) biochemical marker "usefulness" criteria. For some of these markers it may be interesting to also investigate whether the PTMs are the cause or consequence of a certain disease. Copyright 2010 The Canadian Society of Clinical Chemists. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381482     DOI: 10.1016/j.clinbiochem.2010.03.015

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  53 in total

Review 1.  From glycophenotyping by (plant) lectin histochemistry to defining functionality of glycans by pairing with endogenous lectins.

Authors:  Herbert Kaltner; Gabriel García Caballero; Anna-Kristin Ludwig; Joachim C Manning; Hans-Joachim Gabius
Journal:  Histochem Cell Biol       Date:  2018-05-05       Impact factor: 4.304

Review 2.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

Review 3.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

4.  Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids.

Authors:  Varun Gauba; Jan Grünewald; Vanessa Gorney; Lisa M Deaton; Mingchao Kang; Badry Bursulaya; Weijia Ou; Richard A Lerner; Christian Schmedt; Bernhard H Geierstanger; Peter G Schultz; Teresa Ramirez-Montagut
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

Review 5.  Feeling Things Out: Bidirectional Signaling of the Cell-ECM Interface, Implications in the Mechanobiology of Cell Spreading, Migration, Proliferation, and Differentiation.

Authors:  Andrew E Miller; Ping Hu; Thomas H Barker
Journal:  Adv Healthc Mater       Date:  2020-02-09       Impact factor: 9.933

6.  Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology.

Authors:  Efstathios Vassiliadis; Claudia P Oliveira; Mario R Alvares-da-Silva; Chen Zhang; Flair J Carrilho; Jose T Stefano; Fabiola Rabelo; Leila Pereira; Camila R Kappel; Kim Henriksen; Sanne Skovgård Veidal; Ben Vainer; Kevin L Duffin; Claus Christiansen; Diana J Leeming; Morten Karsdal
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

Review 7.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

Review 8.  Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.

Authors:  V Balouz; F Agüero; C A Buscaglia
Journal:  Adv Parasitol       Date:  2016-11-14       Impact factor: 3.870

9.  Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker development.

Authors:  Efstathios Vassiliadis; Natasha Barascuk; Morten A Karsdal
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

10.  Autoimmune smoke and fire--coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: a cross-sectional analysis.

Authors:  Vered Bieber; Arnon D Cohen; Tamar Freud; Nancy Agmon-Levin; Smadar Gertel; Howard Amital
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.